Figure 3. TGFβ2 modulates proliferation and growth of EMCMs.
A. The addition of 1 ng/mg Tgf-β2 during stretch results in 20% reduction in proliferation (1 +/− 0.05 vs 0.80 +/− 0.05; p<0.05; n=3). B. Embryonic cardiomyocytes treated with ITD-1, a Tgfβr2 inhibitor, are 69% larger (1.40×106 +/−0.10 vs 0.83×106+/− 0.03; p<0.001; n=3).